MedTrace Logo

Safety and Tolerability of STP206 in Healthy Adult Subjects

NCT00922324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-05-17

No results posted yet for this study

Summary

The study will assess the safety, tolerability and fecal shedding of STP206 when given as a single dose and when given as daily doses for one week.

Conditions

  • Healthy

Interventions

DRUG

STP206 or vehicle control

STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days

Sponsors & Collaborators

  • Leadiant Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Taha Keilani, MD · Leadiant Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-06-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00922324 on ClinicalTrials.gov